demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 hospitalized
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
janus kinase (JAK) inhibitor
baricitinib ACTT-2 ... COV-BARRIER RECOVERY Cantini Rodriguez-Garcia Tziolos COV-BARRIER ...
ruxolitinib Cao DEVENT
TD-0903
TD-0903 10mg Singh ...
TD-0903 1mg Singh ...
TD-0903 3mg Singh ...
tofacitinib STOP-COVID ... Murugesan

1 studies excluded by filtering options 2

6415 Cantini, 2020 2310excludednot a RCTrisk of bias not avaialble